At a glance
What is it—and why does it matter?
iGlarLixi is a fixed-ratio co-formulation that includes the peptide lixisenatide together with insulin glargine 100 U/mL. The lixisenatide-containing iGlarLixi showed a larger baseline-to-Week-24 HbA1c reduction than IDegAsp when IDegAsp was injected before dinner (LS mean difference -0.29%).
Sources for this introduction: [1] [2]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
Identity
iGlarLixi is a fixed-ratio co-formulation that includes the peptide lixisenatide together with insulin glargine 100 U/mL.
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“To compare the efficacy and safety of the fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with premixed insulin degludec plus insulin aspart (IDegAsp) according to the injection time of IDegAsp.”
Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study. · AIMS
pubmed:42186210:e0f2e8a4a121:e0f2e8a4a121
How does it work?
Target, response, and disposition.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
What has been studied?
What the evidence says.
Study findings
In this randomized comparison, the lixisenatide-containing iGlarLixi produced a larger baseline-to-Week-24 HbA1c reduction than IDegAsp when IDegAsp was injected before lunch (LS mean difference -0.24%).
- Reported result
- least squares mean difference -0.24% [-2.3 mmol/mol]
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Glycated haemoglobin (HbA1c) reductions from baseline to Week 24 were greater with iGlarLixi than IDegAsp injected before lunch (least squares mean difference -0.24% [-2.3 mmol/mol])”
Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study. · RESULTS
pubmed:42186210:e0f2e8a4a121:e0f2e8a4a121
Study findings
The lixisenatide-containing iGlarLixi showed a larger baseline-to-Week-24 HbA1c reduction than IDegAsp when IDegAsp was injected before dinner (LS mean difference -0.29%).
- Reported result
- -0.29% [-3.2 mmol/mol]
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Glycated haemoglobin (HbA1c) reductions from baseline to Week 24 were greater with iGlarLixi than IDegAsp injected before lunch (least squares mean difference -0.24% [-2.3 mmol/mol]) or dinner (-0.29% [-3.2 mmol/mol])”
Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study. · RESULTS
pubmed:42186210:e0f2e8a4a121:e0f2e8a4a121
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, interaction, mechanism, regulatory, safety
- 74 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (38), assurance_score_below_0.72 (31), current_regulatory_source_required (17), extraction_ambiguity (52), high_risk_requires_regulatory_or_two_independent_sources (34), no_direct_support (67), proposal_not_staged (1)
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study. ↗
pubmed · published 2026-08-01 · retrieved 2026-08-27T11:48:55Z
Publication history and provenance
Version 3 · Automated assessment · 2026-08-27T19:16:08Z
6a0535c9bce550f2960273e742be43c8b426527874298054dcf05568650b6e5d